Briellyn Kit
Product Images NDC 68462-316

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Briellyn (NDC 68462-316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure2

A forest plot titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use' showing effect estimates (odds ratios/risk ratios) and confidence intervals for multiple studies conducted between 2002 and 2017. The x-axis indicates effect estimates ranging from -1.5 to 2.0, with study names listed on the left and numerical results on the right. The chart compares breast cancer risk associated with ever or current use of combined oral contraceptives across various cohorts.*

FDA Label Image

Carton (Carton)

BRIELLYN (Norethindrone and Ethinyl Estradiol Tablets) USP 0.4 mg/0.035 mg kit carton. The label indicates it contains 3 blister cards, each with 28 tablets, and is a prescription-only product. Manufactured by Glenmark Pharmaceuticals Ltd., India, and for Glenmark Pharmaceuticals Inc., USA. The label includes dosage instructions and storage conditions, with the Glenmark logo on both front and side panels.*

FDA Label Image

Chemical Structures (Image 01)

Chemical structure diagram showing the molecular formulas and molecular weights of Norethindrone USP and Ethinyl Estradiol USP, the active ingredients in BRIELLYN. The structures depict the steroid backbone and functional groups specific to each compound.*

FDA Label Image

Figure 1 (Image 02)

A bar chart titled "Figure 1 Circulatory Disease Mortality Rates per 100,000 Women-Years by Age, Smoking Status and Oral Contraceptive Use." It shows mortality rates for four groups: Ever-Users (Nonsmokers), Controls (Nonsmokers), Ever-Users (Smokers), and Controls (Smokers) across four age ranges: 15-24, 25-34, 35-44, and 45+. Mortality rates rise with age, notably highest among Ever-Users who are smokers in the 45+ age group.*

FDA Label Image

Glenmark Logo2 (Image 03)

FDA Label Image

Glenmark Logo1 (Image 04)

FDA Label Image

Img-1 (Img 1)

The image is an instructional diagram illustrating the 28-pill pack of BRIELLYN, consisting of Norethindrone and Ethinyl Estradiol tablets. It shows the weekly layout of pills from Sunday through Saturday for four weeks. Light peach pills represent active tablets taken during the first three weeks, while white to off-white pills represent inactive tablets taken in the fourth week. Arrows indicate the sequence of pill intake across days and weeks.*

FDA Label Image

Img-2 (Img 2)

An instructional illustration showing a hand peeling off and placing a day label on a weekly medication kit for Norethindrone and Ethinyl Estradiol tablets. The kit includes circular and capsule-shaped tablet wells arranged in four rows labeled Week 1 to Week 4, with weekdays indicated above the first row. The diagram guides correct day labeling placement for the medication schedule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.